<DOC>
	<DOCNO>NCT02969369</DOCNO>
	<brief_summary>A study evaluate safety tolerability SEP363856 subject Parkinson 's Disease Psychosis</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Tolerability SEP-363856 Subjects With Parkinson 's Disease Psychosis</brief_title>
	<detailed_description>This multicenter , randomize , parallel-group , double-blind , placebo-controlled study evaluate efficacy , safety , tolerability SEP-363856 flexibly dose 25 , 50 , 75 mg/day 6 week male female subject ≥ 55 year age clinical diagnosis PDP . The study randomize approximately 36 subject 2 treatment group 2:1 ratio ( approximately 24 subject SEP-363856 12 placebo ) . The study consist 4 period : Screening/washout Period ( 14 day prior Lead-in ) , Lead-in Period ( 2 week prior Baseline ) , Double-blind treatment Period ( 6 week ) , Follow-up Period ( 1 week last dose ) show following figure . All post-Baseline clinic visit window ± 2 day relative date Baseline visit ( Visit 3 ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<criteria>1 . Subject , caregiver , and/or legally authorize representative understands willing sign inform consent participate study . 2 . Subject must willing able comply study procedure visit schedule must able follow verbal write instruction . 3 . Subject male postmenopausal female ≥ 55 year age . 4 . Subject meet establish diagnostic criterion Parkinson 's disease least one year duration , consistent UK Brain Bank criteria 5 . Subject psychotic symptom begin diagnosis PD least one month , occur least weekly month prior screening ( accord subject caregiver ) , severe enough warrant treatment antipsychotic . 6 . Subject combine score least 6 individual score least 4 neuropsychiatric inventory ( NPI ) Item A ( delusion ) and/or Item B ( hallucination ) . 7 . Subject Minimental status examination ( MMSE ) score &gt; 21 point 30 . 8 . Subject caregiver ( spouse family member ) require attend visit able provide study information various scale NPI Zarit 22 scale . 9 . Subject take antiparkinsonian drug deep brain stimulation , stable dose/dose regimen setting 3 month enrolment . 10 . Female subject must postmenopausal define amenorrheic great two year appropriate clinical profile . 11 . Male subject female partner ( ) childbearing potential must agree avoid father child use acceptable method birth control screen least 30 day last study drug administration . 12 . Subject , opinion Investigator , medically stable base screen medical history , PE , neurological examination , vital sign , clinical laboratory value ( hematology , serum chemistry , urinalysis , lipid panel , coagulation panel , thyroid panel , serum prolactin ) . 13 . Subject stable living arrangement time screen . 1 . Subject psychosis secondary toxic metabolic disorder . 2 . Subject atypical Parkinson 's disease , Parkinsonism secondary medication neurodegenerative disorder , progressive supranuclear palsy multiple system atrophy . 3 . Subject dementia diagnose concurrent Parkinson 's disease , motor symptom begin less one year onset dementia symptom consistent diagnosis lewy body dementia ( LBD ) , psychosis occur ablative stereotaxic surgery . 4 . Subject fail 2 antipsychotic agent give adequate dos least 4 week within 1 year screening . 5 . Subject stroke uncontrolled serious medical neurological illness within 6 month baseline . 6 . Subject answer `` yes '' `` Suicidal Ideation '' Item 4 ( active suicidal ideation intent act , without specific plan ) Item 5 ( active suicidal ideation specific plan intent ) C SSRS Screening ( ie , past one month ) , baseline ( ie , since last visit ) . 7 . Subject tolerate venipuncture poor venous access would cause difficulty collect blood sample . 8 . Subject participate investigational drug study receive investigational drug within 30 day ( long halflife know ≥ 150 hour ) prior screen visit , currently participate another clinical study . Subject previously receive SEP 363856 . 9 . Subject clinically significant unstable medical condition clinically significant chronic disease opinion Investigator , would limit subject 's ability complete and/or participate study : 10 . Subject hematological ( include deep vein thrombosis ) bleeding disorder , renal , metabolic , endocrine , pulmonary , gastrointestinal , urological , cardiovascular , hepatic , neurologic , allergic disease clinically significant unstable ( except untreated , asymptomatic , seasonal allergy time dose ) . 11 . Subject history malignancy within 5 year prior Screening visit , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Pituitary tumor duration exclude . 12 . Subject disorder history condition , previous gastrointestinal surgery ( eg , cholecystectomy , vagotomy , bowel resection , surgical procedure ) may interfere drug absorption , distribution , metabolism , excretion , gastrointestinal motility , pH , clinically significant abnormality hepatic renal system , history malabsorption . 13 . Subject Alcohol Substance Abuse Disorder ( DSM 5 criterion ) . The exception caffeine nicotine . 14 . Subject clinically significant abnormal 12 lead ECG may jeopardize subject 's ability complete study screen 12 lead ECG demonstrate one following : heart rate &gt; 100 beat per minute , QRS &gt; 120 m , QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 m ( male ) , QTcF &gt; 470 m ( female ) , PR &gt; 220 ms. 15 . Subjects know human immunodeficiency virus ( HIV ) seropositivity exclude . 16 . Female subject pregnant lactating . 17 . Subject presence history medically diagnose , clinically significant psychiatric disorder . 18 . Subject significant risk harm him/herself others accord Investigator 's judgment . 19 . Subject attempt suicide within 3 month prior screen . 20 . Subject history allergic reaction suspect sensitivity substance contain formulation . 21 . Subject clinically significant abnormal laboratory value ( hematology , serum chemistry , urinalysis , lipid panel , coagulation panel , thyroid panel , serum prolactin , urine drug screen ( Note : abnormal finding may clinically significant questionable significance discuss Medical Monitor prior include subject ) . 22 . Subjects serum alanine transaminase ( ALT ) aspartate transaminase ( AST ) level ≥ 3 time , serum blood urea nitrogen ( BUN ) creatine ≥ 1.5 X upper limit reference range provide central laboratory require retesting . If retesting , laboratory value remain equal ULN , subject exclude . 23 . Subjects random ( nonfasting ) blood glucose screen ≥ 200 mg/dL ( 11.1 mmol/L ) HbA1c ≥ 6.5 % exclude . 24 . Subject prolactin concentration &gt; 100 ng/mL screen history pituitary adenoma . 25 . Subject 's BMI ≥ 30 mg/kg/m2 . 26 . Subject experience significant blood loss ( ≥ 473 mL ) donate blood within 60 day prior first dose study drug ; donate plasma within 72 hour prior first dose study drug intend donate plasma blood undergo elective surgery study participation within 60 day last study visit . 27 . Subject consume 300 mg caffeine per day ( 5 cup coffee equivalent caffeinated beverage ) . 28 . Subject use disallow prescription medication anticipates need disallow medication participation study . Subject staff member relative staff member . 29 . Subject opinion Investigator , unsuitable way participate study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>105 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson 's Disease Psychosis</keyword>
</DOC>